4-(Methoxymethyl)-1-pentanol | 411239-79-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-(Methoxymethyl)-1-pentanol
• 英文别名: 5-methoxy-4-methyl-pentan-1-ol；5-Methoxy-4-methylpentan-1-ol
• CAS: 411239-79-7
• 化学式: C₇H₁₆O₂
• 分子量: 132.203
• InChiKey: ZGGMULXHIOGJPG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  9
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-(Methoxymethyl)-1-pentanol 在 吡啶 、 氯化亚砜 作用下， 生成 isopropyl-(5-methoxy-4-methyl-pentyl)-amine
  参考文献：
  名称：

  Synthesis of the Branched Chain 5-Isopropylaminoamyl and 4-Isopropylaminobutyl Ethers and of the Bromides Derived from Them^1,2

  摘要：

  DOI：

  10.1021/ja01159a071
• 作为产物：
  描述：

  环氧乙烷 、 alkaline earth salt of/the/ methylsulfuric acid 在 乙醚 作用下， 生成 4-(Methoxymethyl)-1-pentanol
  参考文献：
  名称：

  Synthesis of the Branched Chain 5-Isopropylaminoamyl and 4-Isopropylaminobutyl Ethers and of the Bromides Derived from Them^1,2

  摘要：

  DOI：

  10.1021/ja01159a071

文献信息

• Protein-Proteophor Complexes
  申请人：Complex Biosystems GmbH

  公开号：EP2090323A1

  公开（公告）日：2009-08-19

  The application relates to a composition comprising a hyperbranched polymer attached to a core and a biologically active moiety. The biologically active moiety is attached to the core by means of a substantially non-enzymatically cleavable linker L. The composition can be used to deliver the biologically active moiety to its target.

  本申请涉及一种组合物，该组合物由连接到核心和生物活性分子的超支化聚合物组成。生物活性分子通过基本上不可酶解的连接体 L 连接到芯上。
• Kirmse, Wolfgang; Rode, Klaus, Chemische Berichte, 1987, vol. 120, p. 847 - 848
  作者：Kirmse, Wolfgang、Rode, Klaus

  DOI：——

  日期：——
• KIRMSE W.; RODE K., CHEM. BER., 120,(1987) N 5, 847-848
  作者：KIRMSE W.、 RODE K.

  DOI：——

  日期：——
• HIV INTEGRASE INHIBITORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP2349276A2

  公开（公告）日：2011-08-03
• [EN] HIV INTEGRASE INHIBITORS<br/>[FR] INHIBITEURS DE L'INTÉGRASE DU VIH
  申请人：MERCK & CO INC

  公开号：WO2010042392A2

  公开（公告）日：2010-04-15

  Compounds of Formula I are inhibitors of HIV integrase and inhibitors of HIV replication: (I), wherein X1, X2, Y, R1A, R1B, R2 and R3 are defined herein. The compounds are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset or progression of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se (or as hydrates or solvates thereof) or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Processes for making compounds of Formula I and intermediates thereof are also described.